Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
China Opens Door to Stronger U.S. Trade Ties Amid Rising Tensions 
Asian Stocks Rebound as Trump Delays Iran Strike Deadline 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Bubs Australia will manufacture and distribute Bubs’ Chinese-label goat milk infant formula in China according to new Chinese standards. under an agreement with Heilongjiang Ubeite Dairy Group (HUG).
The new standards will come into effect in February 2023 .
The “ultra-premium” infant formula has been specially developed for Chinese infants using easily-digestible A2 goat-milk protein, sn2 palmitate (OPO), lactoferrin prebiotics, and nucleotides.
HUG has started submission with the State Administration for Market Regulation (SAMR) to renew its registration in line with China’s new GB standards for exclusive use under the Bubs brand.
According to Kristy Carr, Bubs founder and CEO, they have built strong brand trust and loyalty with Chinese families through marketing and selling Bubs English label infant formula products via the crossborder eCommerce channel, which accounts for around 20 percent of total Chinese infant formula sales.
If approved by SAMR, the formula will give Bubs access to the remaining 80 percent of China’s $25.9 billion infant formula market.
Bubs will also enter into a joint venture agreement, where it will hold a 75 percent interest, with Zhitong Health Technology to distribute its Chinese label goat infant formula products.
Bubs Australia expects to launch its product in the second half of FY23, subject to receiving SAMR approval.
